Baseline urinary osteopontin levels are associated with the improvement of metabolic syndrome.

While serum osteopontin (OPN)'s established role in cardiometabolic risk is recognized, its potential as a predictor of metabolic syndrome (MetS) improvement through a urine assay has not yet been demonstrated. In this study, we propose its potential predictive role over a 12-month period of standard care, with the ability to complement anthropometric measures. Hierarchical clustering revealed a notable association of urinary OPN (uOPN) with MetS criteria and overcame anthropometric measures in predicting the improvement at 12 months (OR of 2.74 [95% CI 1.32 to 6.29]). uOPN significantly contributed to the homogeneity of the nodes in the random forest and ultimately enhanced the performance of anthropometric measures when assessed for accuracy and area under the curve (AUC). Our findings offer insights into potential applications in cardiometabolic medicine for uOPN, which is easily detectable in non-invasive biological samples through an affordable assay. • Cardiometabolic diseases are linked with aging process. • Osteopontin has an established role in Cardiometabolic risk, but not when assayed in urine. • Osteopontin has a potential as predictor of metabolic syndrome improvement over 12 months of standard of care. • Osteopontin may improve the accuracy of anthropometric measure in defining cardiometabolic risk. [ABSTRACT FROM AUTHOR]